Many oral contraceptives have been studied in the treatment of acne (Table 3). These include those containing ethinyl estradiol in combination with cyproter- one acetate (Diane, Dianette), ethynodiol diacetate (Demulen), levonorgestrel (TriPhasil, Alesse), norgestimate (Ortho Tri-Cyclenw), desogesterel (Desogen), and drosperinone (Yasmin, Yaz). Numerous studies point to the efficacy of ethinyl estradiol/cyproterone acetate oral contraceptives (Diane and Dianette) in the treatment of acne. Reductions in inflammatory lesion count on the order of
50% to 75% have been reported (44,45). Two large studies involving a total of approximately 500 women with moderate acne were conducted with ethinyl estradiol 35 mg/norgestimate (Ortho Tri-Cyclen). Improvement in inflammatory lesions, total lesions, and global assessment was noted with this oral contraceptive after six months of treatment (46,47). There was a 50% to 60% improvement in inflammatory lesions. Decreases in serum free testosterone and an increase in sex hormone-binding globulin were noted in the active group. Two large, six-month, placebo-controlled trials (350 and 371 women, respectively) were conducted
FIGURE 2 (See color insert.) Adult female with acne of the lower face.
using ethinyl estradiol 20 mg/levonorgestrel (Alesse) in the treatment of acne (48,49). In each study, the oral contraceptive demonstrated significantly greater reduction in acne lesion counts and improvement in global assessment scores com- pared with placebo. The reduction in inflammatory lesion count was on the order of
47%. A study of 128 women with mild-to-moderate acne compared the efficacy of ethinyl estradiol 30 mg/drospirenone (Yasmin) and ethinyl estradiol 35 mg/cypro- terone acetate (Diane-35) in the treatment of acne for nine cycles (50). Both treat- ments produced comparable reductions in acne lesion counts, with an approximate 60% reduction in inflammatory lesion count. Both treatments also reduced sebum production and yielded comparable increases in sex hormone- binding globulin. Two large placebo-controlled studies involving a total of approxi- mately 593 women with moderate acne, found improvement in inflammatory lesions, total lesions, global assessment, and quality of life in women who were treated for six months with a triphasic oral contraceptive that contains doses of
20 to 35 mg of ethinyl estradiol in combination with 1.0 mg norethindrone acetate (Estrostep) (51). In these studies, inflammatory lesion counts were reduced by approximately 47% (51).
Oral contraceptives that have been approved for the treatment of acne in the United States include ethinyl estradiol 35 mg/norgestimate (Ortho Tri-Cyclen) ethinyl estradiol 20 to 35 mg/norethindrone acetate (Estrostep), and ethinyl estra- diol 20 mg/drospirenone (Yaz).